JP2020518256A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518256A5 JP2020518256A5 JP2019560197A JP2019560197A JP2020518256A5 JP 2020518256 A5 JP2020518256 A5 JP 2020518256A5 JP 2019560197 A JP2019560197 A JP 2019560197A JP 2019560197 A JP2019560197 A JP 2019560197A JP 2020518256 A5 JP2020518256 A5 JP 2020518256A5
- Authority
- JP
- Japan
- Prior art keywords
- crrna
- cell
- genetically modified
- stem
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 43
- 210000004027 cell Anatomy 0.000 claims description 37
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 108090000790 Enzymes Proteins 0.000 claims description 15
- 102000004190 Enzymes Human genes 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 241001112693 Lachnospiraceae Species 0.000 claims description 5
- 238000010362 genome editing Methods 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 210000004986 primary T-cell Anatomy 0.000 claims description 5
- 238000004520 electroporation Methods 0.000 claims description 4
- 241000194036 Lactococcus Species 0.000 claims description 3
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 3
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 241000604451 Acidaminococcus Species 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 238000009172 cell transfer therapy Methods 0.000 claims description 2
- 238000011519 second-line treatment Methods 0.000 claims description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical group C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023092842A JP7622138B2 (ja) | 2017-05-04 | 2023-06-06 | Ｃｒｉｓｐｒ／ｃｐｆ１を用いる、ｔ細胞における遺伝子編集のための組成物および方法 |
| JP2025005127A JP2025061285A (ja) | 2017-05-04 | 2025-01-15 | Ｃｒｉｓｐｒ／ｃｐｆ１を用いる、ｔ細胞における遺伝子編集のための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762501371P | 2017-05-04 | 2017-05-04 | |
| US62/501,371 | 2017-05-04 | ||
| PCT/US2018/030644 WO2018204493A1 (en) | 2017-05-04 | 2018-05-02 | Compositions and methods for gene editing in t cells using crispr/cpf1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023092842A Division JP7622138B2 (ja) | 2017-05-04 | 2023-06-06 | Ｃｒｉｓｐｒ／ｃｐｆ１を用いる、ｔ細胞における遺伝子編集のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020518256A JP2020518256A (ja) | 2020-06-25 |
| JP2020518256A5 true JP2020518256A5 (enExample) | 2021-06-10 |
| JP7292213B2 JP7292213B2 (ja) | 2023-06-16 |
Family
ID=64016339
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019560197A Active JP7292213B2 (ja) | 2017-05-04 | 2018-05-02 | Ｃｒｉｓｐｒ／ｃｐｆ１を用いる、ｔ細胞における遺伝子編集のための組成物および方法 |
| JP2023092842A Active JP7622138B2 (ja) | 2017-05-04 | 2023-06-06 | Ｃｒｉｓｐｒ／ｃｐｆ１を用いる、ｔ細胞における遺伝子編集のための組成物および方法 |
| JP2025005127A Pending JP2025061285A (ja) | 2017-05-04 | 2025-01-15 | Ｃｒｉｓｐｒ／ｃｐｆ１を用いる、ｔ細胞における遺伝子編集のための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023092842A Active JP7622138B2 (ja) | 2017-05-04 | 2023-06-06 | Ｃｒｉｓｐｒ／ｃｐｆ１を用いる、ｔ細胞における遺伝子編集のための組成物および方法 |
| JP2025005127A Pending JP2025061285A (ja) | 2017-05-04 | 2025-01-15 | Ｃｒｉｓｐｒ／ｃｐｆ１を用いる、ｔ細胞における遺伝子編集のための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12029760B2 (enExample) |
| EP (1) | EP3619302A4 (enExample) |
| JP (3) | JP7292213B2 (enExample) |
| CN (1) | CN110785489A (enExample) |
| CA (1) | CA3062165A1 (enExample) |
| WO (1) | WO2018204493A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2734621B1 (en) | 2011-07-22 | 2019-09-04 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9840699B2 (en) | 2013-12-12 | 2017-12-12 | President And Fellows Of Harvard College | Methods for nucleic acid editing |
| WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| IL258821B (en) | 2015-10-23 | 2022-07-01 | Harvard College | Nucleobase editors and their uses |
| KR20250103795A (ko) | 2016-08-03 | 2025-07-07 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| CA3033327A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| JP7588390B2 (ja) | 2016-10-14 | 2024-11-22 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 核酸塩基エディターのａａｖ送達 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| CN110662556A (zh) | 2017-03-09 | 2020-01-07 | 哈佛大学的校长及成员们 | 癌症疫苗 |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| BR112019019655A2 (pt) | 2017-03-23 | 2020-04-22 | Harvard College | editores de nucleobase que compreendem proteínas de ligação a dna programáveis por ácido nucleico |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| JP2020534795A (ja) | 2017-07-28 | 2020-12-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物 |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| CN111770994B (zh) * | 2017-10-02 | 2025-03-18 | 基因编辑有限公司 | 修饰的cpf1引导rna |
| KR20250107288A (ko) | 2017-10-16 | 2025-07-11 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| WO2020122104A1 (ja) * | 2018-12-11 | 2020-06-18 | 国立大学法人京都大学 | ゲノムｄｎａに欠失を誘導する方法 |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| EP3942042A1 (en) | 2019-03-19 | 2022-01-26 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| EP3956349A1 (en) | 2019-04-17 | 2022-02-23 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| WO2021226558A1 (en) | 2020-05-08 | 2021-11-11 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| WO2024038168A1 (en) * | 2022-08-19 | 2024-02-22 | UCB Biopharma SRL | Novel rna-guided nucleases and nucleic acid targeting systems comprising such |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3215623A4 (en) * | 2014-11-06 | 2018-09-26 | President and Fellows of Harvard College | Cells lacking b2m surface expression and methods for allogeneic administration of such cells |
| US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| WO2017023803A1 (en) * | 2015-07-31 | 2017-02-09 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| JP2018532402A (ja) | 2015-09-24 | 2018-11-08 | クリスパー セラピューティクス アーゲー | Ｒｎａプログラム可能エンドヌクレアーゼの新規のファミリーならびにゲノム編集および他の適用におけるそれらの使用 |
-
2018
- 2018-05-02 WO PCT/US2018/030644 patent/WO2018204493A1/en not_active Ceased
- 2018-05-02 US US16/609,628 patent/US12029760B2/en active Active
- 2018-05-02 EP EP18795128.0A patent/EP3619302A4/en active Pending
- 2018-05-02 CA CA3062165A patent/CA3062165A1/en active Pending
- 2018-05-02 JP JP2019560197A patent/JP7292213B2/ja active Active
- 2018-05-02 CN CN201880042161.3A patent/CN110785489A/zh active Pending
-
2023
- 2023-06-06 JP JP2023092842A patent/JP7622138B2/ja active Active
-
2024
- 2024-06-12 US US18/740,688 patent/US20240316107A1/en active Pending
-
2025
- 2025-01-15 JP JP2025005127A patent/JP2025061285A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020518256A5 (enExample) | ||
| Porto et al. | Base editing: advances and therapeutic opportunities | |
| AU2016276702B2 (en) | CRISPR/CAS-related methods and compositions for improving transplantation | |
| CN110139675B (zh) | 用具有工程化稳定的内源性foxp3基因表达的cd4t细胞治疗自身免疫疾病的方法 | |
| JP2018522072A5 (enExample) | ||
| JP2016500262A5 (enExample) | ||
| JP2020528738A (ja) | ｉｎ ｖｉｔｒｏでＴ細胞中のターゲット遺伝子をノックアウトするための方法及び前記方法で使用されるｃｒＲＮＡ | |
| CN113646006A (zh) | 用于营养不良型大疱性表皮松解症的治疗剂 | |
| Zych et al. | Application of genome editing techniques in immunology | |
| Chen | Efficient gene editing in primary human T cells | |
| CN117716026A (zh) | 具有氧化应激抗性的间充质干细胞、其制备方法及用途 | |
| CN113226336A (zh) | 一种在细胞中递送基因的方法 | |
| AU2021300358A1 (en) | Methods and compositions for editing the B2M locus in B cells | |
| JP2005521632A5 (enExample) | ||
| Ma et al. | Get ready for the CRISPR/Cas system: A beginner's guide to the engineering and design of guide RNAs | |
| Roy | Immune responses to CRISPR-Cas protein | |
| Goryaev et al. | Genome-editing and biomedical cell products: current state, safety and efficacy | |
| O’Brien et al. | CRISPR-mediated gene editing for the surgeon scientist | |
| Lal et al. | Curative Therapy of Sickle Cell Disease Using Gene Editing Technologies | |
| Liao et al. | Gene Editing in Hematopoietic Stem Cells | |
| JPWO2020198587A5 (enExample) | ||
| CN118355348A (zh) | 乙型肝炎病毒(hbv)敲除 | |
| CN114369621B (zh) | 一种基因生物制剂及其制备方法和应用 | |
| JPWO2022093863A5 (enExample) | ||
| JPWO2021224395A5 (enExample) |